The effects of the most frequent treatment options were also validated by testing the response of the system to the inhibition of IL-17, TNFα, IL-12, and IL-23, all of which are the main targets of the biologics used to treat moderate-to-severe psoriasis.8 The gene discussed is IL17A; the disease is psoriasis.